Published in final edited form as:

Angew Chem Int Ed Engl. 2012 July 16; 51(29): 7217–7220. doi:10.1002/anie.201202291.

Hybrid organic-inorganic inhibitors of a PDZ-peptide interaction that regulates CFTR endocytic fate**

Rituparna Kundu^[a], Dr. Patrick[^]R. Cushing^{[b],[++]}, Dr. Brian[^]V. Popp^{[a],[+]}, Yu Zhao^[b], Prof. Dean[^]R. Madden^{*,[b]}, and Prof. Zachary[^]T. Ball^{*,[a]}

^[a]Department of Chemistry, Rice University 6100 Main St., Houston, TX 77005 (USA)

^[b]Department of Biochemistry, Dartmouth Medical School 7200 Vail Bldg., Rm. 408, Hanover, NH 03755-3844 (USA)

Organic-inorganic inhibitors

Protein-protein interactions (PPIs) play key roles in cellular processes and human disease, but the proteins involved often lack compact pockets accessible to traditional ligand-discovery methods. As first shown for enzyme inhibitors,^[1] multiple weak interactions can be combined to yield polyvalent^[2] ligands with enhanced potency and specificity, and this strategy has now been extended to “undruggable” PPI targets.^[3] In this paper, we extend the ideas of fragment-based PPI inhibition to design hybrid structures utilizing cooperative organic-inorganic binding to a target protein (Figure 1a). In particular, we engineer a stable rhodium(II) metallopeptide that displaces representative peptide ligands from the PDZ domain of the CFTR-associated ligand (CAL). PDZ domains are a family of peptide-binding PPI modules named for the first three members: PSD-95, Dlg, and ZO-1.

In an aqueous environment, metal-ligand interactions offer potentially dramatic stability increases compared to non-covalent organic interactions, which are typically weak (<1 kcal/mol). However, taking advantage of this possibility is challenging. Recruiting endogenous metal ions can stabilize a protein-inhibitor interface,^[4] but the low *in vivo* availability of transition-metal ions is a major limitation.^[5] Stable metal-based protein inhibitors have a significant history, generally based on exchange-inert, coordinatively saturated species that serve as structural scaffolds.^[6] However, with the exception of DNA-metal enzyme inhibitors,^[7] few stable inhibitors have been able to exploit reversible coordination chemistry across the binding interface.^[8]

To do so, a discrete organic-inorganic complex must contain a stable organic-metal linkage, while allowing ligand exchange at the metal center in order to bind targeted side chains. Fortunately, di-metal “pinwheel” structures, such as rhodium(II) tetracarboxylate, have well differentiated ligand environments containing both kinetically inert, equatorial κ^2 -carboxylate ligands and kinetically labile axial ligand sites (e.g., Figure 1b),^[9] with a demonstrated capability to bind biologically relevant thiol and imidazole compounds in a

[**]This work was funded by NSF (CHE-1055569), the John S. Dunn GCC Robert A. Welch Collaborative Grant Program, the Virginia and L.E. Simmons Family Foundation, and the Robert A. Welch Foundation (C-1680). Additional support was provided by NIH (R01-DK075309, P20-RR018787/GM103413, and T32-GM008704), the Cystic Fibrosis Foundation Research Development Program (STANTO11R0), and a Hitchcock Foundation PPG.

*zb1@rice.edu <urla><http://www.ztb.rice.edu/></url> . *dean.r.madden@dartmouth.edu <urlb><http://www.dartmouth.edu/~madden/></url> .

[+]Current address: Bennett Department of Chemistry, West Virginia University P.O. Box 6045, Morgantown, WV 26506 (USA)

[++]Current address: ArQule 19 Presidential Way, Woburn MA 01801 (USA)

reversible manner.^[10] The toxicity^[11] of rhodium(II) complexes and their interactions with nucleic acids^[12] and proteins^[13] have been reported.

We happened upon the idea that rhodium(II) centers could form stabilizing secondary contacts at the periphery of a protein binding interface while examining the coiled-coil assembly of rhodium(II) metalloptides with histidine-containing peptides (Figure 1b).^[14] Based on established models,^[15] a rhodium(II) center linked to a coil at positions *a* and *e* of a heptad repeat (*abcdefg*, Table 1) would be proximal to position *g* of the complementary peptide, E3_gX. We found that coordination of appropriate position *g* side chains strongly stabilizes the coiled coil. For example, thermal denaturation of a mixture of E3_gH and K3_{a,e}Rh₂ revealed a high melting temperature ($T_m = 66.1$ °C; Figure 2 and Table 1, entry 3), in contrast to simple E3/K3 dimers^[15] and to control experiments with non-coordinating phenylalanine ($T_m = 39.5$ °C, entry 1). This coiled-coil stabilization reflects a specific interaction of the rhodium center.

Moving the histidine residue away from the interface, to position *c*, led to a drop in T_m to 47.0 °C (Table 1, entry 8, and Figure 2). The addition of large concentrations of imidazole, either before or after coiled-coil assembly, also led to a significant drop in melting temperature (to 46 °C, Figure 2), providing evidence for a reversible metal-ligand interaction (entry 4). Finally, upon assembly with the E3_gH coil, the metalloptide K3_{a,e}Rh₂ exhibits a blue shift of the UV-vis absorption peak from 587 nm to 567 nm, consistent with a rhodium(II) tetracarboxylate containing axial nitrogen or sulfur ligands.^[10a,16]

Other Lewis basic side chains also facilitate stabilization. Coiled-coil assemblies with either glutamate (E3_gE) or methionine (E3_gM) peptides also exhibit elevated T_m values (50.2 °C and >70 °C, respectively), consistent with carboxylate–rhodium or stronger thioether–rhodium interactions (Table 1, entries 3, 5–7). So far as we are aware, T_m values of 65–70 °C represent the most stable intermolecular coiled coils yet reported for such a short peptide (21 amino acids),^[17] similar to stabilities achieved with covalent crosslinking.^[18] Insertion of cysteine at the same position, on the other hand, lead to a coiled coil with *decreased* stability (entry 8). Preliminary modeling indicates the cysteine side chain is too short to reach the rhodium center without disrupting the coiled coil.

To extend the concept of organic-inorganic cooperativity to the discovery of potent PPI inhibitors, we examined interactions between the CAL PDZ domain (CALP) and the cystic fibrosis transmembrane conductance regulator (CFTR). The C-terminus of CFTR interacts with several proteins (e.g. CAL, NHERF1, ways).^[19] Despite its potential value as a target, inhibiting CALP is distinctly difficult due to its broad specificity and comparatively low baseline affinity.^[20] We recently combined a screen of inverted peptide arrays with *in vitro* fluorescence polarization measurements to identify selective CALP inhibitors.^[20,21] However, the potency of these inhibitors remains modest, with $K_i = 1.3$ μM.

The CAL PDZ domain contains several histidine residues near the peptide-binding site, making it an attractive target for a hybrid organic–inorganic approach to inhibitor design (Figure 3a).^[22] To test the potential contributions of rhodium-based interactions to CALP inhibitor affinity, we adapted known methods^[11a,23] to prepare metalloptides based on sequences known to interact with CALP. PDZ binding requires free C-terminal carboxylates, and we found it convenient to metalate a peptide containing both C-terminal and side-chain carboxylates and then to isolate the side-chain-modified metalloptide from the product mixture by HPLC (Figure 4).

We measured inhibitor equilibrium dissociation (K_i) constants, using fluorescence anisotropy to observe the displacement of a fluorescent reporter peptide (Figure 3b and

Table 2). The VQDTRL peptide, derived from the native target CFTR, has weak CALP affinity. Direct incorporation of a rhodium(II) center at the aspartate side-chain carboxylate (VQD^{Rh}TRL) resulted in a decrease in the apparent inhibitory constant (K_i) relative to the parent peptide (Table 2, entries 1-2), but when the new value (6.3 μ M) was compared to a simple rhodium complex, Rh₂(OAc)₄, the improvement was not statistically significant. The apparent affinity of VQD^{Rh}TRL was also comparable to that of a metallopeptide derived from a non-binding, scrambled control sequence, QLD^{Rh}VTR (Table 2, entry 4). Together, these data suggest that the effects seen with rhodium(II) addition at the P⁻³ site (P⁰ = C-terminal residue) of VQDTRL are not specific.

We designed two metallopeptides having a site of rhodium attachment at the P⁻⁶ position, because structural analysis of the CALP domain^[22] indicated that the P⁻⁶ position should be proximal to the His301 residue in this target (Figure 3a). Both new metallopeptides exhibited statistically significant and reproducible affinity enhancement relative to controls (Table 2, entries 5–8). Working with a sequence (EWPTSII) carrying a glutamate side chain at the P⁻⁶ position, metalation increased binding affinity from 65 to 1.7 μ M, a ~40-fold enhancement. An even larger enhancement was seen with the sequence EVQSTR_L, which contains the dominant C-terminal tetrapeptide identified by array screens.^[24] The metallopeptide E^{Rh}VQSTR_L bound with the highest affinity yet reported for CALP (0.56 μ M), a 75-fold change relative to the parent peptide (Table 2 and Figure 3b). HSQC footprinting spectra in the presence of either the peptide or metallopeptide (supporting information) were well dispersed—confirming binding to the canonical PDZ site, with localized differences.

A CALP-H301A mutant was prepared to ascertain the role of His301 in metallopeptide affinity. This mutant binds the parent EVQSTR_L with a K_i value of 80 μ M, only slightly (~2-fold) weaker than the wild-type protein. However, the mutant binds the metallopeptide with an apparent K_i of 9.2 μ M, a >16-fold loss of affinity relative to wild-type, consistent with the predicted His301–rhodium ligation.

To provide an independent demonstration of rhodium-based affinity enhancement and to establish the efficacy of rhodium metallopeptides in a more complex environment, a pulldown inhibition assay was performed using epithelial cell lysate. Relative to the non-metalated control, the metallopeptide E^{Rh}VQSTR_L exhibits improved inhibition, demonstrating that the affinity gains carry over to a more physiological environment (Figure 5).

The metallopeptide E^{Rh}VQSTR_L (K_i = 0.56 μ M) is the first reported inhibitor with sub-micromolar affinity for the CAL PDZ domain and is significantly shorter than decameric single-micromolar alternatives.^[21b] The ability to quickly generate a potent inhibitor for a recalcitrant protein target demonstrates that combining organic inhibitors with coordination chemistry is a viable strategy to inhibit protein–protein interactions. In addition, comparative binding studies with the CALP-H301A mutant and with P⁻³ metalated peptides indicate that rhodium mediates affinity enhancement through peripheral interactions specific to the given target binding site. This capability bodes well for the development of inhibitors not only for PDZ domains, but for other structural classes of protein regulators as well.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

References

- [1]a). Hajduk PJ, Greer J. *Nat. Rev. Drug Discov.* 2007; 6:211–219. [PubMed: 17290284] b) Erlanson DA, Wells JA, Braisted AC. *Annu. Rev. Biophys. Biomol. Struct.* 2004; 33:199–223. [PubMed: 15139811] c) DeLano WL. *Curr. Opin. in Struct. Biol.* 2002; 12:14–20. [PubMed: 11839484]
- [2]a). Mammen M, Choi S-K, Whitesides GM. *Angew. Chem.* 1998; 110:2908–2953. *Angew. Chem. Int. Ed.* 1998; 37:2754–2794. b) Kiessling LL, Strong LE, Gestwicki JE. *Annu. Rep. Med. Chem.* 2000; Vol. 35:321–330. c) Gestwicki JE, Cairo CW, Strong LE, Oetjen KA, Kiessling LL. *J. Am. Chem. Soc.* 2002; 124:14922–14933. [PubMed: 12475334]
- [3]a). Verdine GL. *Mol. Cancer Ther.* 2007; 6:3623S–3623S. b) Hu X, Sun J, Wang H-G, Manetsch R. *J. Am. Chem. Soc.* 2008; 130:13820–13821. [PubMed: 18811158] c) Kulkarni SS, Hu X, Doi K, Wang H-G, Manetsch R. *ACS Chem. Biol.* 2011; 6:724–732. [PubMed: 21506574]
- [4]a). Salgado EN, Radford RJ, Tezcan FA. *Acc. Chem. Res.* 2010; 43:661–672. [PubMed: 20192262] b) Katz BA, Clark JM, Finer-Moore JS, Jenkins TE, Johnson CR, Ross MJ, Luong C, Moore WR, Stroud RM. *Nature.* 1998; 391:608–612. [PubMed: 9468142] c) Iyaguchi D, Kawano S, Takada K, Toyota E. *Bioorg. Med. Chem.* 2010; 18:2076–2080. d) Fazal MA, Roy BC, Sun S, Mallik S, Rodgers KR. *J. Am. Chem. Soc.* 2001; 123:6283–6290. [PubMed: 11427052]
- [5]. Schiffmann R, Heine A, Klebe G, Klein CDP. *Angew. Chem.* 2005; 117:3686–3689. *Angew. Chem. Int. Ed.* 2005; 44:3620–3623.
- [6]a). Feng L, Geisselbrecht Y, Blanck S, Wilbuer A, Atilla-Gokcumen GE, Filippakopoulos P, Kräling K, Celik MA, Harms K, Maksimoska J, Marmorstein R, Frenking G, Knapp S, Essen L-O, Meggers E. *J. Am. Chem. Soc.* 2011; 133:5976–5986. [PubMed: 21446733] b) Takeuchi T, Böttcher A, Quezada CM, Meade TJ, Gray HB. *Bioorg. Med. Chem.* 1999; 7:815–819. [PubMed: 10400334] c) Venkatraman S, Wu W, Prongay A, Girijavallabhan V, George Njoroge F. *Bioorg. Med. Chem. Lett.* 2009; 19:180–183. [PubMed: 19022670] d) LeBeau AM, Singh P, Isaacs JT, Denmeade SR. *Chem. Biol.* 2008; 15:665–674. [PubMed: 18635003] e) Wilbuer A, Vlecken DH, Schmitz DJ, Kräling K, Harms K, Bagowski CP, Meggers E. *Angew. Chem.* 2010; 122:3928–3932. *Angew. Chem. Int. Ed.* 2010; 49:3839–3842. f) Xie P, Williams DS, Atilla-Gokcumen GE, Milk L, Xiao M, Smalley KSM, Herlyn M, Meggers E, Marmorstein R. *ACS Chem. Biol.* 2008; 3:305–316. [PubMed: 18484710]
- [7]a). Harney AS, Lee J, Manus LM, Wang P, Ballweg DM, LaBonne C, Meade TJ. *Proc. Natl. Acad. Sci. U. S. A.* 2009; 106:13667–13672. [PubMed: 19666616] b) Hurtado RR, Harney AS, Heffern MC, Holbrook RJ, Holmgren RA, Meade TJ. *Mol. Pharmaceutics.* 2012; 9:325–333.
- [8]. Hocharoen L, Cowan JA. *Chem. Eur. J.* 2009; 15:8670–8676. [PubMed: 19685535]
- [9]. Chifotides, HT.; Dunbar, KR. *Multiple Bonds Between Metal Atoms*. 3rd ed. Cotton, FA.; Murillo, C.; Walton, RA., editors. Springer; New York: 2005. p. 465–589.
- [10]a). Jakimowicz P, Ostropolska L, Pruchnik FP. *Met.-Based Drugs.* 2000; 7:201–209. [PubMed: 18475946] b) Das K, Simmons EL, Bear JL. *Inorg. Chem.* 1977; 16:1268–1271.
- [11]a). Zaykov AN, Popp BV, Ball ZT. *Chem. Eur. J.* 2010; 16:6651–6659. [PubMed: 20411535] b) Howard RA, Sherwood E, Erck A, Kimball AP, Bear JL. *J. Med. Chem.* 1977; 20:943–946. [PubMed: 874969]
- [12]a). Chifotides HT, Dunbar KR. *Acc. Chem. Res.* 2005; 38:146–156. [PubMed: 15709734] b) Angeles-Boza AM, Chifotides HT, Aguirre JD, Chouai A, Fu PKL, Dunbar KR, Turro C. *J. Med. Chem.* 2006; 49:6841–6847. [PubMed: 17154514] c) Rainen L, Howard RA, Kimball AP, Bear JL. *Inorg. Chem.* 1975; 14:2752–2754. d) Kang M, Chouai A, Chifotides HT, Dunbar KR. *Angew. Chem.* 2006; 118:6294–6297. *Angew. Chem. Int. Ed.* 2006; 45:6148–6151.
- [13]a). Lee SH, Chao DL, Bear JL, Kimball AP. *Cancer Chemother. Rep.* 1. 1975; 59:661–663. b) Howard RA, Spring TG, Bear JL. *Cancer Res.* 1976; 36:4402–4405. [PubMed: 1000490]
- [14]a). Popp BV, Ball ZT. *J. Am. Chem. Soc.* 2010; 132:6660–6662. [PubMed: 20420453] b) Popp BV, Ball ZT. *Chem. Sci.* 2011; 2:690–695.
- [15]. Litowski JR, Hodges RS. *J. Biol. Chem.* 2002; 277:37272–37279. [PubMed: 12138097]
- [16]a). Dennis AM, Howard RA, Bear JL. *Inorg. Chim. Acta.* 1982; 66:L31–L34. b) Das K, Bear JL. *Inorg. Chem.* 1976; 15:2093–2095.

- [17]. Woolfson, DN.; Parry, DAD.; Squire, JM. *Adv. Protein Chem.* Vol. Vol. 70. Academic Press; 2005. p. 79-112.
- [18]a). Antonsson P, Kammerer RA, Schulthess T, Hänisch G, Engel J. *J. Mol. Biol.* 1995; 250:74–79. [PubMed: 7602598] b) Hoshino M, Yumoto N, Yoshikawa S, Goto Y. *Protein Sci.* 1997; 6:1396–1404. [PubMed: 9232640] c) Taylor CM, Keating AE. *Biochemistry.* 2005; 44:16246–16256. [PubMed: 16331985]
- [19]a). Cheng J, Moyer BD, Milewski M, Loffing J, Ikeda M, Mickle JE, Cutting GR, Li M, Stanton BA, Guggino WB. *J. Biol. Chem.* 2002; 277:3520–3529. [PubMed: 11707463] b) Estell K, Braunstein G, Tucker T, Varga K, Collawn JF, Schwiebert LM. *Mol. Cell. Biol.* 2003; 23:594–606. [PubMed: 12509457] c) Milewski MI, Mickle JE, Forrest JK, Stafford DM, Moyer BD, Cheng J, Guggino WB, Stanton BA, Cutting GR. *J. Cell Sci.* 2001; 114:719–726. [PubMed: 11171377]
- [20]. Cushing PR, Fellows A, Villone D, Boisguerin P, Madden DR. *Biochemistry.* 2008; 47:10084–10098. [PubMed: 18754678]
- [21]a). Vouilleme L, Cushing PR, Volkmer R, Madden DR, Boisguerin P. *Angew. Chem.* 2010; 122:10108–10112. *Angew. Chem. Int. Ed.* 2010; 49:9912–9916. b) Cushing PR, Vouilleme L, Pellegrini M, Boisguerin P, Madden DR. *Angew. Chem.* 2010; 122:10103–10107. *Angew. Chem. Int. Ed.* 2010; 49:9907–9911.
- [22]. Piserchio A, Fellows A, Madden DR, Mierke DF. *Biochemistry.* 2005; 44:16158–16166. [PubMed: 16331976]
- [23]. Zaykov AN, MacKenzie KR, Ball ZT. *Chem. Eur. J.* 2009; 15:8961–8965. [PubMed: 19637261]
- [24]. Roberts KE, Cushing PR, Boisguerin P, Madden DR, Donald BR. *PLoS Comput. Biol.* 2012; 8:e1002477. [PubMed: 22532795]

Figure 1.

(a) Conceptual depiction of a hybrid organic-inorganic inhibitor. (b) Axial coordination in $E3_gH-K3_{a,e}Rh_2$ stabilizes the coiled coil. (c) Sequences used in this study. Lower-case grey letters represent positions on a helical-wheel depiction (see Table 1).

Figure 2. Selection of thermal denaturation profiles for stoichiometric mixtures of E3H and $K_{3a,c}Rh_2$. Vertical lines indicate melting temperature (T_m). See Table 1 for sample conditions and T_m values.

Figure 3.

(a) Structure of the CAL PDZ domain (orange ribbon) bound to a CFTR peptide (green stick figure)^[22] All CALP His side chains are shown explicitly (stick figures colored by element; grey = C, blue = N). (b) Fluorescence anisotropy displacement isotherms for candidate CALP inhibitors. K_i values are reported in Table 2.

Figure 4.
Representative synthesis of a PDZ-binding metalloprotein.

Figure 5. Metalation improves inhibitor potency. (a) Western blot of native CAL captured from epithelial lysates,^[21b] in the presence of increasing concentrations of EVQSTR peptide with (+Rh) or without (-Rh) rhodium. (b) Quantification reveals dose-dependent inhibition of CAL pulldown (PD) by the metalated peptide (n=3).

Table 1Thermal denaturation of metallopeptide coiled coils.^[a]

entry	sequence	E3X	T_m (°C)
1		E3 _g F	39.5
2		E3 _g E	50.2
3		E3 _g H	66.1
4 ^[b]		E3 _g H +50 mM imid.	46.0
5		E3 _g M	>75
6 ^[c]		E3 _g M	70.4
7		E3 _g C	33.5
8		E3 _c H	47.0

^[a]Standard condns: equimolar mixtures of E3X and K3_{a,e}Rh2 in aq buffer (pH 5.9–6.2) were monitored by CD (222 nm) from –5 to 95 °C at 1 °C/min. All peptides 100 μM unless otherwise noted.

^[b]CD monitored at 225 nm.

^[c]Peptide concentration 33 μM.

Table 2Metallopeptide inhibitors of CALP.^[a]

entry	peptide	sequence	K_i (μM)
1	1		320 $\pm$ 43
2	1-Rh	VQDTRL	6.3 ^[b] $\pm$ 0.7
3	2	^{Rh} VQDTRL	>500
4	2-Rh		10.0 ^[b] $\pm$ 0.9
5	3	QLDVTR	65 $\pm$ 5
6	3-Rh	^{Rh} QLDVTR	1.7 ^[c] $\pm$ 0.2
7	4		42 $\pm$ 5
		EWPTSII	
		^{Rh} EWPTSII	
8	4-Rh		0.56 ^[c] $\pm$ 0.08
		EVQSTR	
		^{Rh} EVQSTR	

^[a] Inhibitor equilibrium dissociation (K_i) constants were determined for cognate peptide/metallopeptide pairs.

^[b] All rhodium(II) complexes, including Rh₂(OAc)₄ (K_i =13 $\pm$ 5 μM) exhibit nonspecific inhibition, establishing an upper bound for these measurements.

^[c] K_i value significantly different from Rh₂(OAc)₄ (p<0.05, n=3).

INH: Cooperative binding of organic and inorganic fragments provides a strategy for the potent inhibition of protein–protein interactions. Targeting specific Lewis-basic side chains in peripheral regions of the protein binding site for coordination to a rhodium(II) center improves the affinity of weak affinity protein ligands.

PDZ

Inhibitors

Rhodium

Metallopeptide

CFTR